2014 ASCO AM Public - Sunday

269

Chicago, IL - The 2014 ASCO Annual Meeting - "Martine J. Piccart, M.D., Ph.D., at Abstract #LBA4: ""First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T_L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC),"" Plenary Session Keyword: AM14_Martine_Piccart" at the American Society of Clinical Oncology Annual Meeting here today, Sunday June 1, 2014. More than 30,000 physicians, researchers, health care professionals, cancer survivors and patient advocates are expected to attend the 50th Anniversary meeting at the McCormick Convention Center. The Annual Meeting highlights the latest findings in all major areas of oncology from basic through clinical and epidemiological studies. Photo by © ASCO/Phil McCarten 2014 Technical Questions: todd@medmeetingimages.com